BIOMAT Database Logo BIOMAT Database Logo

A case of tardive dystonia associated with long-acting injectable paliperidone palmitate. 2016

Chia-Hao Ma, and Yi-Ling Chien, and Chen-Chung Liu, and I-Ming Chen, and Chia-Hsien Lin
Department of Psychiatry, National Taiwan University Hospital, Taiwan.

UI MeSH Term Description Entries
D009770 Obsessive Behavior Persistent, unwanted idea or impulse which is considered normal when it does not markedly interfere with mental processes or emotional adjustment. Obsessions,Behavior, Obsessive,Behaviors, Obsessive,Obsession,Obsessive Behaviors
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003680 Deglutition Disorders Difficulty in SWALLOWING which may result from neuromuscular disorder or mechanical obstruction. Dysphagia is classified into two distinct types: oropharyngeal dysphagia due to malfunction of the PHARYNX and UPPER ESOPHAGEAL SPHINCTER; and esophageal dysphagia due to malfunction of the ESOPHAGUS. Dysphagia,Swallowing Disorders,Esophageal Dysphagia,Oropharyngeal Dysphagia,Deglutition Disorder,Disorders, Deglutition,Dysphagia, Esophageal,Dysphagia, Oropharyngeal,Swallowing Disorder
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004401 Dysarthria Disorders of speech articulation caused by imperfect coordination of pharynx, larynx, tongue, or face muscles. This may result from CRANIAL NERVE DISEASES; NEUROMUSCULAR DISEASES; CEREBELLAR DISEASES; BASAL GANGLIA DISEASES; BRAIN STEM diseases; or diseases of the corticobulbar tracts (see PYRAMIDAL TRACTS). The cortical language centers are intact in this condition. (From Adams et al., Principles of Neurology, 6th ed, p489) Hyperkinetic Dysarthria,Hypokinetic Dysarthria,Scanning Speech,Dysarthosis,Dysarthria, Flaccid,Dysarthria, Guttural,Dysarthria, Mixed,Dysarthria, Scanning,Dysarthria, Spastic,Dysarthoses,Dysarthria, Hyperkinetic,Dysarthria, Hypokinetic,Dysarthrias,Dysarthrias, Flaccid,Dysarthrias, Guttural,Dysarthrias, Hyperkinetic,Dysarthrias, Hypokinetic,Dysarthrias, Mixed,Dysarthrias, Scanning,Dysarthrias, Spastic,Flaccid Dysarthria,Flaccid Dysarthrias,Guttural Dysarthria,Guttural Dysarthrias,Hyperkinetic Dysarthrias,Hypokinetic Dysarthrias,Mixed Dysarthria,Mixed Dysarthrias,Scanning Dysarthria,Scanning Dysarthrias,Scanning Speechs,Spastic Dysarthria,Spastic Dysarthrias,Speechs, Scanning
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068882 Paliperidone Palmitate A benzisoxazole derivative and active metabolite of RISPERIDONE that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST and SEROTONIN 5-HT2 RECEPTOR ANTAGONIST. It is an ANTIPSYCHOTIC AGENT used in the treatment of SCHIZOPHRENIA. 3-(2-(4-(6-fluoro-3-(1,2-benzisoxazolyl))-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one,9-Hydroxy-risperidone,9-Hydroxyrisperidone,9-OH-risperidone,Invega,Invega Sustenna,Paliperidone,R 76477,R-76477,9 Hydroxy risperidone,9 Hydroxyrisperidone,9 OH risperidone,Palmitate, Paliperidone,R76477,Sustenna, Invega
D000071057 Tardive Dyskinesia Drug-related movement disorder characterized by uncontrollable movements in certain muscles. It is associated with a long-term exposure to certain neuroleptic medications (e.g., METOCLOPRAMIDE). Tardive Dystonia,Dyskinesia, Tardive,Dyskinesias, Tardive,Dystonia, Tardive,Dystonias, Tardive,Tardive Dyskinesias,Tardive Dystonias
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Chia-Hao Ma, and Yi-Ling Chien, and Chen-Chung Liu, and I-Ming Chen, and Chia-Hsien Lin
Angioedema Associated With Long-Acting Injectable Paliperidone Palmitate: A Case Report.
December 2017, Journal of clinical psychopharmacology,
Chia-Hao Ma, and Yi-Ling Chien, and Chen-Chung Liu, and I-Ming Chen, and Chia-Hsien Lin
Bilateral Pretibial Edema Associated with Paliperidone Palmitate Long-acting Injectable: A Case Report.
May 2017, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology,
Chia-Hao Ma, and Yi-Ling Chien, and Chen-Chung Liu, and I-Ming Chen, and Chia-Hsien Lin
Long-acting injectable paliperidone palmitate in a haemodialysis patient with schizophrenia.
August 2021, The Australian and New Zealand journal of psychiatry,
Chia-Hao Ma, and Yi-Ling Chien, and Chen-Chung Liu, and I-Ming Chen, and Chia-Hsien Lin
Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.
May 2017, Psychopharmacology bulletin,
Chia-Hao Ma, and Yi-Ling Chien, and Chen-Chung Liu, and I-Ming Chen, and Chia-Hsien Lin
Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable: A Database Report and Case Study.
January 2019, Journal of clinical psychopharmacology,
Chia-Hao Ma, and Yi-Ling Chien, and Chen-Chung Liu, and I-Ming Chen, and Chia-Hsien Lin
Paliperidone Palmitate-Associated Severe Refractory Tardive Dyskinesia With Tardive Dystonia: Management and Six-Months Follow-Up.
August 2016, Journal of clinical psychopharmacology,
Chia-Hao Ma, and Yi-Ling Chien, and Chen-Chung Liu, and I-Ming Chen, and Chia-Hsien Lin
Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
July 2018, Psychological medicine,
Chia-Hao Ma, and Yi-Ling Chien, and Chen-Chung Liu, and I-Ming Chen, and Chia-Hsien Lin
A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.
February 2012, The international journal of neuropsychopharmacology,
Chia-Hao Ma, and Yi-Ling Chien, and Chen-Chung Liu, and I-Ming Chen, and Chia-Hsien Lin
Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models.
March 2024, bioRxiv : the preprint server for biology,
Chia-Hao Ma, and Yi-Ling Chien, and Chen-Chung Liu, and I-Ming Chen, and Chia-Hsien Lin
Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation.
January 2022, Therapeutic advances in psychopharmacology,
Copied contents to your clipboard!